The absence of institutional selling and strong buying from mega-passive firms may signal growing confidence in MacroGenics' pipeline or upcoming catalysts. Traders should monitor for near-term clinical updates or partnerships as potential triggers.
MGNX drugs
MGNX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $1.94entry
- T+1 · 9mo ago −2.06%α −1.15% · $1.90
- T+5 · 8mo ago +21.65%α +22.86% · $2.36
- T+20 · 8mo ago +42.27%α +50.21% · $2.76
- T+60 · 6mo ago +130.41%α +121.09% · $4.47
How similar events traded
Executive Summary
Three major institutional investors, Morgan Stanley, Wells Fargo, and UBS, significantly increased their positions in MacroGenics (MGNX) during Q4 2024, collectively adding $2.8M in new holdings with no institutional selling observed. The cluster is driven by large passive managers doubling down on the stock, suggesting growing institutional interest despite the company's small market cap of $126M.
Key Financial Metrics
Institutional Positions
Net institutional flow: $2.8M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | DOUBLED | +245.3% | $3.6M | $2.5M |
| UBS | ADD | +60.3% | $552.0K | $204.0K |
| Wells Fargo | ADD | +45.4% | $97.0K | $29.0K |
Key Facts
- Morgan Stanley doubled its position, increasing value by $2.5M (from $1.1M to $3.6M)
- Wells Fargo and UBS added $29K and $204K respectively
- No institutional sellers reported in the quarter
- Total net buying: $2.8M across three mega-passive institutions
Financial Impact
3 institutions accumulated $2.8M in new positions, increasing total institutional holdings by 207% quarter-over-quarter
Risk Factors
- All buyers are passive managers, which may reflect index inclusion or rebalancing rather than fundamental conviction
- Small market cap makes the stock vulnerable to volatility if institutions reverse
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-MGNX-2024-Q4 |
Track record
21 reports on MGNX
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +32.85% at T+60 after the Apr 8, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 settles Feb 12
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 settles Feb 12
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 settles Feb 11
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 settles Feb 2
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 settles Feb 2
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 settles Jan 22
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 settles Jan 22
- Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 settles Jan 21
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers